[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lymphoid-malignancies":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Lymphoid Malignancies",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06047886","UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy",[11],"Phase 1","RECRUITING","2026-08-26T02:16:46.951087Z","2026-05-05T02:43:29.130088Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[11],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.704804Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[25],"Phase 1\u002FPhase 2","2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",[],[]]